ELAHE MOHAZAB: Open Payments
NPI 1770993610 · AUSTELL, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$938 in 13 payments from 7 companies in 2025. Trend: 2023 $1,657 · 2024 $982 · 2025 $938
Food & beverage: $938
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $334 |
| Janssen Pharmaceuticals, Inc | 1 | $142 |
| Luye Pharma (USA) Ltd. | 1 | $125 |
| Supernus Pharmaceuticals, Inc. | 1 | $111 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| Axsome Therapeutics, Inc. | 1 | $88 |
| ABBVIE INC. | 2 | $38 |
Products named: INGREZZA, SPRAVATO, ERZOFRI EXTENDED-RELEASE, Qelbree, UZEDY, Auvelity, VRAYLAR.
Industry payments across GA — which companies pay providers there.
